VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
PITTSBURGH, Dec. 18, 2025 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...
VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global ...
The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of ...
Act, 2025 revamps tobacco taxation, introducing steep excise duties on cigarettes, chewing tobacco, and smoking mixtures to ...
Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid ...
A peanut patch immunotherapy demonstrated efficacy and safety in desensitizing young children with peanut allergy in a phase 3 study.
DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing ...
DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, ...
An experimental pain-relieving drug delivery method for farm animals using microneedle patches may not have delivered an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback